XBP1 and familial pancreatic carcinoma: These analyses revealed higher proliferation (Q1) of CD28-positive (Figure 5B) and CD38-positive (Figure 5C) cells within XBP1-CTL by lenalidomide treatment against breast cancer (MDA-MB231; 37% CD28+, 39% CD38+ proliferation), colon cancer (SW480; 24% CD28+, 26% CD38+ proliferation) or pancreatic cancer (Panc1; 18% CD28+, 11% CD38+ proliferation) cells.